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studies of the oligomerisation 
mechanism of a cystatin-based 
engineered protein scaffold
Matja Zalar1, sowmya Indrakumar2, Colin W. Levy1, Richard B. Tunnicliffe1, 
Günther H. J. peters2 & Alexander p. Golovanov  1
Engineered protein scaffolds are an alternative to monoclonal antibodies in research and drug design 
due to their small size, ease of production, versatility, and specificity for chosen targets. One key 
consideration when engineering such proteins is retaining the original scaffold structure and stability 
upon insertion of target-binding loops. SQT is a stefin A derived scaffold protein that was used as a 
model to study possible problems associated with solution behaviour of such aptamers. We used an 
SQT variant with AU1 and Myc insertion peptides (SQT-1C) to study the effect of peptide insertions on 
protein structure and oligomerisation. The X-ray structure of monomeric SQT-1C revealed a cystatin-like 
fold. Furthermore, we show that SQT-1C readily forms dimers and tetramers in solution. NMR revealed 
that these oligomers are symmetrical, with inserted loops comprising the interaction interface. two 
possible mechanisms of oligomerisation are compared using molecular dynamics simulations, with 
domain swap oligomerisation being thermodynamically favoured. We show that retained secondary 
structure upon peptide insertion is not indicative of unaltered 3D structure and solution behaviour. 
therefore, additional methods should be employed to comprehensively assess the consequences of 
peptide insertions in all aptamers, particularly as uncharacterized oligomerisation may alter binding 
epitope presentation and affect functional efficiency.
Monoclonal antibodies (mAbs) represent the major class of molecules used for affinity binding studies in research 
and are the most commonly used diagnostic and biotherapeutic agents1,2. Despite their versatility and wide appli-
cability, production of mAbs is costly and poses many challenges due to their high molecular weight (>140 kDa) 
and structural complexity, including post-translational modifications typically requiring mammalian expression 
systems3. In light of these inherent problems of mAbs, alternative approaches to find high-affinity binders for a 
specific target have been developed, including using smaller antibody fragments4, or using engineered protein 
scaffolds (also called protein aptamers) based on non-immunoglobulin proteins5,6. Protein aptamers are designed 
by insertion of a short (typically up to 10–15 residues) peptide containing the desired binding epitope into a 
loop of a stable protein scaffold7. In principle, these aptamers mimic the antibody-based molecular recognition 
mechanism, but have a much smaller frame, simpler design, do not have post-translational modifications, and are 
often obtained using less demanding recombinant expression systems7,8. To date more than 50 structurally diverse 
non-immunoglobulin protein scaffolds have been developed9,10. While they were initially used for construction 
and screening of combinatorial protein libraries for protein recognition7,11, they have since then become widely 
used in studies of protein function and molecular interaction12–14, as diagnostic tools15,16 and biosensors17, as well 
as imaging agents18,19 and biotherapeutics20–22.
The correct presentation of peptide epitopes for binding, and hence activity of the scaffold-based binding 
proteins, strongly depends on maintaining scaffold structure and solution properties. Often, point mutations 
are introduced to improve structural robustness and thermodynamic stability of scaffolds23, while tags are added 
to improve their solubility24. Whereas rigorous protein library evaluation is usually performed to check scaf-
fold’s affinity and specificity towards the target protein, their 3D structural characteristics and solution behaviour 
are not always characterized comprehensively13,25–27. During scaffold development, the effect of loop inser-
tions on thermal stability and retention of secondary structure is typically tested, however large variations are 
1Manchester institute of Biotechnology and School of chemistry, faculty of Science and engineering, University 
of Manchester, 131 Princess Street, Manchester, M1 7DN, UK. 2Department of Chemistry, Technical University of 
Denmark, Building 207, DK-2800 Kgs, Lyngby, Denmark. Correspondence and requests for materials should be 
addressed to A.P.G. (email: A.Golovanov@manchester.ac.uk)
Received: 1 April 2019
Accepted: 6 June 2019
Published: xx xx xxxx
OPEN
2Scientific RepoRts |          (2019) 9:9067  | https://doi.org/10.1038/s41598-019-45565-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
acceptable22,28–30. Although it has been shown previously that insertion of specific peptides needed for function 
can significantly perturb scaffold structure31,32, the origins and consequences of such instabilities have not been 
studied in detail. A better understanding of these problems is required, perhaps by looking at specific case studies 
first.
SQT is one of many engineered protein scaffolds: it is based on human stefin A (SteA, also known as cysta-
tin A) that has three possible insertion sites for peptides, namely the N-terminus, loop 1 (L1) and loop 2 (L2). 
Although it has been previously shown to retain secondary structure upon insertion of a variety of peptide com-
binations into its insertion sites28, no tertiary or higher-order structural characterization has been reported.
Here we have used an SQT variant, named SQT-1C, with AU1 and Myc peptides inserted into loops L1 and 
L2, respectively, as a model to understand the effect of inserted peptides on scaffold structure, stability and oli-
gomerisation properties. X-ray crystallography confirmed that monomeric SQT-1C exhibits typical cystatin fold 
but only in very specific conditions, when crystallised in the presence of 19% dioxane. However, in solution and 
in the absence of dioxane, monomeric SQT-1C exists in dynamic equilibrium with domain-swapped dimeric and 
dominant tetrameric species. NMR was used to determine the amino acid residues involved in oligomerisation 
of the SQT variant, while molecular dynamics (MD) simulations and molecular mechanics energies combined 
with the generalized Born surface area continuum solvation (MM-GBSA) calculations were employed to explore 
the driving forces of SQT-1C self-association. We show that inserted peptide regions play a crucial role in scaffold 
protein oligomerisation via domain swapping, leading to significantly different conformations and surface expo-
sure of these binding epitopes in monomeric, dimeric and tetrameric forms. We anticipate that due to general 
similarity of protein folding driving forces, the instabilities revealed in this case study may also be observed in 
other small protein aptamers, therefore justifying a thorough characterization of the “functional” conformations 
using an appropriate range of techniques, helping to troubleshoot designs early in their development processes.
Results
purification of sQt reveals defined oligomeric species. The variant of a model protein scaffold 
SQT28 with AU1 and Myc peptide insertions and C-terminal hexa-histidine tag, named SQT-1C, was expressed 
and purified. After separation of refolded SQT-1C on size exclusion column, three distinct elution peaks were 
identified, corresponding to SQT-1C monomer, dimer and tetramer, as confirmed by size-exclusion chroma-
tography (SEC) coupled with multi-angle light scattering (MALS) (Supplementary Fig. S1). In addition, a low 
intensity polydispersed peak corresponding to higher oligomeric species was observed, however its concentra-
tion remained marginal even after extended periods of time. The isolated monomeric fraction oligomerised over 
time, again producing the same three well defined peaks on the chromatogram, with the tetramer species being 
predominant. Similarly, isolated dimeric and tetrameric species equilibrated into a mixture of all three species 
within 24 hours (Fig. 1).
Melting temperature of SQT-1C was 54 °C ± 1 °C, as measured by changes in intrinsic fluorescence 
(Supplementary Fig. S1), compared to 79.9 °C reported for SQT alone28, which indicated that the inserted pep-
tides significantly destabilized the scaffold. To understand the underlying mechanism and pathway of SQT-1C 
oligomerisation, we attempted to crystallise fresh monomeric, dimeric and tetrameric SQT-1C fractions.
Crystallised SQT-1C exhibits a cystatin-like monomer fold. SQT-1C crystallised only from the 
freshly-purified tetrameric fraction and in the presence of 19% dioxane, surprisingly yielding monomeric struc-
ture, which was solved to 2.5 Å resolution. Essential data collection and refinement statistics are shown in Table 1, 
and extended statistics in Table S1. The structure coordinates were submitted to the Protein Data Bank under 
accession code 6QB2. Interpretable electron density was observed for polypeptide regions R4-L48 and A93-N113 
whilst residues D49-F75 were visible but less well ordered, indicating higher flexibility of this region. The SQT-1C 
monomer exhibits a cystatin-like architecture with five anti-parallel β-sheets and a perpendicular α-helix (Fig. 2), 
showing that peptide insertions into loop regions do not affect the SQT scaffold backbone.
Figure 1. Analysis of SQT-1C oligomeric states. SEC traces of (a) monomeric, (b) dimeric and (c) tetrameric 
SQT-1C reinjected onto the column immediately after purification (solid line) and after 24 h of incubation at 
25 °C (dashed line).
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SQT-1C*
Data Collection
Space group P 4212
Cell dimensions
a,b,c (Å) 96.12, 96.12, 29.86
α,β,γ (°) 90, 90, 90
Resolution range (Å) 42.99–2.5 (2.589–2.5)
Rmerge 0.05822 (0.9239)
I/σI 17.39 (2.37)
Completeness (%) 99.79 (99.60)
Redundancy 11.9 (12.6)
Refinement
Resolution (Å) 2.5
No. reflections 5207 (497)
Rwork 0.2725 (0.4411)
Rfree 0.2892 (0.6248)
No. atoms
  Protein 753
  Protein residues 95
B-factors (Å2)
Average 104.03
Protein 104.03
R.m.s. deviations
Bond lengths (Å) 0.002
Bond angles (°) 0.63
Number of TLS groups 1
Table 1. Crystallography data collection and refinement statistics for SQT-1C. *Statistics for the highest 
resolution shell are shown in parenthesis.
Figure 2. Overview of SQT-1C structure. (a) Cartoon representation of SQT-1C structure coloured by 
secondary structure element with termini and chain breaks labelled with residue numbers. (b) Electron density 
and cartoon representation of SQT-1C structure. Black electron density is 2Fo-Fc map contoured at 1 sigma 
level and brown electron density composite omit iterative rebuild map contoured at 1 sigma level. This map 
shows good density for the core of the protein but only weak density for the loops. For clarity, the electron 
density of the helix region has been omitted.
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For further analysis using MD simulations, the missing polypeptide stretches were added to the X-ray struc-
ture with homology modelling (see Methods section for full details). PDBePISA analysis33 of protein inter-
faces did not identify any specific interactions that would result in the formation of stable oligomers indicating 
that SQT-1C crystallises as a monomer. SQT-1C oligomerisation state in solution under crystallisation condi-
tions was further assessed by SEC, which revealed that in the presence of 19% dioxane SQT-1C is monomeric 
(Supplementary Fig. S2). NMR spectra of SQT-1C in the presence of dioxane were also consistent with the mon-
omeric form of the protein (Supplementary Fig. S2) additionally confirming that presence of high percentage of 
dioxane shifts the SQT-1C equilibrium exclusively towards the monomeric state, possibly by strengthening the 
salt-bridges within the protein34.
SQT-1C forms symmetric oligomers in solution. SQT-1C monomer in normal buffer solution in the 
absence of dioxane freely oligomerises into dimers and tetramers over time. Far–UV CD spectra of freshly- 
separated SQT-1C monomers showed little difference when compared to dimers and tetramers, indicating 
that the overall fold of SQT-1C is retained upon oligomerisation (Supplementary Fig. S1). Structural changes 
occurring upon SQT-1C oligomerisation were further assessed using NMR spectroscopy. The direct backbone 
assignment of SQT-1C was not possible due to signal loss and broadening likely caused by chemical exchange 
between oligomeric species in the intermediate regime. Therefore, another construct, SQT-1N, was used for the 
backbone assignment following a standard sequential assignment strategy (submitted to BioMagResBank, ID 
27757). The N-terminal tag and residues M20-V23, G55, D68-Y70, Y72, I73, G98, K102 and T128 could not be 
unambiguously assigned due to lack of cross-peak connectivities in 3D spectra. The sequence specific assignment 
of SQT-1C was derived from that of SQT-1N, as described in the Methods section. Backbone 1H and 15N chemical 
shift assignments of both constructs are shown in Supplementary Fig. S3. While SQT-1N exhibited better NMR 
spectral properties, it also formed dimers and tetramers, similarly to SQT-1C (Supplementary Fig. S4).
The 1D 1H NMR spectrum of the freshly-purified SQT-1C dimer exhibits line broadening without significant 
signal shifts when compared to the spectrum of monomer, which is expected due to increased molecular weight 
and possibly due to chemical exchange. These effects are even more prominent in the spectrum of the tetrameric 
fraction (Supplementary Fig. S5). Similarly to the 1H spectra, line broadening was observed in 2D 1H-15N HSQC 
spectra of dimers and tetramers but it was not uniform across all peaks (Fig. 3a). This non-uniformity was indica-
tive of the spectral resolution being influenced not only by an increase of molecular weight and local polypeptide 
mobility but also by conformational exchange processes in the intermediate regime. The intensity ratio of peaks 
measured in different oligomeric states of SQT-1C (Fig. 3b) revealed that residues least affected by line broaden-
ing are mostly situated on the part of the protein distant from the engineered N-terminus, L1 and L2. The signals 
from latter regions were severely broadened in 2D 1H-15N HSQC spectra of dimers and tetramers, which further 
suggests their possible involvement in SQT-1C oligomerisation interface (Fig. 3c). Additionally, no significant 
Figure 3. NMR characterization of SQT-1C oligomeric species. (a) Comparison of 1H-15N HSQC spectra 
of freshly isolated monomeric (blue), dimeric (black) and tetrameric (red) SQT-1C indicates symmetrical 
topology of oligomers and conformational exchange in intermediate regime. (b) Dimer-monomer (black) 
and tetramer-monomer (red) peak intensity ratio plotted against SQT-1C residue number. (c) Regions with 
preserved signal intensities were identified and two arbitrary thresholds were set to 0.48 and 0.25, and mapped 
onto the SQT-1C structure. Residues between threshold values are plotted in light blue while residues with 
intensity ratio above 0.48 are coloured with dark blue. They indicate regions of SQT-1C that are less affected by 
oligomerisation.
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chemical shift perturbations or cross peak duplications were observed in 2D 1H-15N HSQC spectra of SQT-1C 
oligomers indicating that both dimeric and tetrameric species have symmetrical topologies and are formed by 
self-association of SQT-1C monomeric units.
To probe the local conformational stability of freshly-prepared SQT-1C monomers, residue-specific hydro-
gen/deuterium (H/D) exchange data on a timescale of minutes were collected using fast acquisition methods and 
fitted to exponential decays, to obtain exchange rates and protection factors (Supplementary Fig. S6). The H/D 
exchange for the whole protein occurs within less than an hour, suggesting that the whole protein fold is desta-
bilised. However, we also observed some site-specific variations of the exchange times, with the amides located 
on the surface of the protein and/or in the loop regions exchanging within minutes or seconds (Supplementary 
Fig. S6). These data supported our hypothesis that SQT-1C has a highly flexible structure undergoing conforma-
tional exchange, consistent with spontaneous partial opening.
Monomeric SQT-1C self-associates into oligomers through inserted peptide loops. Self- 
association of isolated monomeric SQT-1C in solution was monitored by acquiring a series of 1H-15N HSQC 
spectra over a period of 36 h. During this time approximately 70% of the signal intensity was lost due to oligom-
erisation but no chemical shift perturbations were observed (Supplementary Fig. S7). Residue-specific ratios of 
signal intensities at the end and at the beginning of the experiment (If/I0) report on signal loss due to conforma-
tional exchange and increase in rotational correlation time as a consequence of oligomerisation (Fig. 4a). The 
highest (If/I0) values were observed for residues that form β-sheets and the α-helix indicating conformational 
stability of these regions. Conversely, (If/I0) values below average were observed for residues in the N-terminus, 
L1 and L2, indicating regions most affected by conformational exchange and therefore most likely to be involved 
in the process of oligomerisation. Additionally, the most severe broadening of signals was observed for residues 
Q46-T58 and F77-T96 which correspond to inserted peptides in L1 (D49-L54) and L2 (E81-R93) and residues in 
their immediate proximity, as shown in Fig. 4b. Overall, the NMR experiments performed indicated that inserted 
loops together with the N-terminal are involved in SQT-1C oligomerisation.
The slow rates of signal loss and oligomerisation imply a relatively slow loop mediated structural rearrange-
ment leading to symmetrical association of monomers in a non-domain-swapped (NDS) or a domain-swapped 
(DS) manner. Although oligomerisation via domain swapping has been described for the cystatin protein fam-
ily35,36, V48D mutation was engineered in SQT to prevent cystatin-like domain swapping28,29. As the broadening 
of NMR signals upon oligomerisation and symmetrical nature of SQT-1C oligomers made it impossible to distin-
guish between NDS and DS mechanisms from NMR data alone, we have explored the relative stability of different 
oligomer models using MD simulations, to gain insight into the SQT-1C oligomerisation pathway.
Figure 4. NMR signal perturbation mapping of SQT-1C oligomerisation interface. (a) Ratio between signal 
intensity after 36 h incubation at 25 °C (If) and intensity immediately after monomer fraction isolation (I0) plotted 
against residue number. The mean If/I0 ratio is depicted with green line and standard deviation of mean depicted 
in green region. The position of elements of secondary structure is annotated for reference. (b) Mapping of 
oligomerisation interface. If/I0 values per residue for SQT-1C are represented on the structure. The thickness of 
ribbons is inversely correlated to the If/I0 ratio. Residues with lower than average If/I0 ratio are coloured in green 
while the rest are depicted in grey. Unresolved, unassigned and proline residues are shown in black.
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Domain swap is the preferred pathway of SQT-1C oligomerisation. Initial DS SQT-1C dimer and 
tetramer structures were obtained by homology modelling based on the domain-swapped stefin B structure (PDB 
ID 2OCT)37 using I-TASSER38–40. Monomeric unit of stefin B has 43.8% sequence identity to SQT-1C, and 2OCT 
is, to the best of our knowledge, the only tetrameric structure of SQT-1C homolog available for use as a template. 
NDS dimer and tetramer SQT-1C models were obtained by ab-initio docking using the multi-body interface of 
HADDOCK 2.2 webserver41–43. Structures of all four SQT-1C tetramer models together with their chain orien-
tations are shown in Supplementary Figs S8 and S9. For full details also see Supplementary Methods section. All 
SQT-1C oligomer models were subjected to 120 ns MD simulation. For systems that did not converge within this 
timeframe, MD simulations were extended to explore the convergence on a longer timescale. MD simulations 
allowed assessment of relative stability of different models, and for the stable models, to determine the geometry 
of the binding interface and identify residues crucial for the oligomerisation process. Based on backbone RMSDs, 
structures of dimer 2 and tetramer of NDS Cluster 2 were quickly disintegrating, indicating that such oligomers 
would not be stable in solution (Supplementary Fig. S10). The other models converged and were stable for the rest 
of the production runs. For these stable models, we have assessed the effect of oligomerization on loop flexibility, 
and mapped residues involved. In monomeric SQT-1C, N- and C- terminal residues together with inserted loops 
represent regions of increased flexibility, as measured by root mean square fluctuations (RMSF). As expected, 
these regions exhibit lower RMSF values in the dimer simulations, and these are further decreased in tetram-
ers, as the inserted loops together with terminal residues become constrained within the interaction interface 
(Supplementary Fig. S11). The same effect is also seen as a reduction of solvent accessible surface areas (SASA) for 
loop regions when compared to SASA values in monomeric SQT-1C. Whereas solvent exposure of both inserted 
loops in all of the NDS dimers is similar to that of the monomer, in NDS tetramers it is decreased for L1 typically 
to 22–27% of that of a monomer (Supplementary Table S2). In case of DS oligomers, L1 is completely solvent 
inaccessible upon tetramer formation and SASA is significantly decreased in DS dimer, while L2 solvent exposure 
is decreased to 21% when the DS tetramer is formed, but only marginally affected by DS dimerisation.
To further understand the SQT-1C intermolecular interactions at the atomic level, binding free energies of 
each amino acid residue in the SQT-1C oligomers were calculated using the MM-GBSA method implemented 
in AMBER 16 software44,45. We found that while the formation of both NDS and DS SQT-1C oligomers is highly 
energetically favourable, the total interaction energy of DS oligomers is more negative than for NDS oligomers, 
indicating that DS oligomers would be more stable than their NDS analogues (Table 2). This further suggests that 
the domain swap mechanism might be the preferred pathway of SQT-1C oligomerisation. Detailed analysis of 
total free binding energy decomposition revealed that the unfavourable desolvation component (ΔGGB) is com-
pensated for with favourable electrostatic energy (ΔEEEL), van der Waals interaction contribution (ΔEVDW) and 
non-polar solvation energies (ΔENPOL and ΔESURF) (Supplementary Table S3). This implied that both NDS and 
DS oligomerisation pathways are driven by both electrostatic and hydrophobic interactions. To assess whether 
SQT-1C dimer models are consistent with the electron density observed in the crystal, we attempted to superim-
pose the DS SQT-1C homology model onto the SQT-1C crystal lattice (Supplementary Fig. S12). However, such 
a model was clearly incompatible with the packing observed in the crystalline lattice, encroaching into two of the 
symmetry related molecules, in agreement with SQT-1C being monomeric in the crystal state.
Inserted loops are crucial for SQT-1C oligomer formation. To further understand SQT-1C oligom-
erisation at the amino acid level, per residue free energy contributions to tetramerisation binding free energy 
were calculated using the MM-GBSA method and are shown in Fig. 5a–d. Residues with an energy contribution 
larger than 2.5 kcal/mol were considered as interaction hotspots and are highlighted in Fig. 5e–g. In the NDS 
oligomers, even though domain orientation between the three tetramer clusters varies, T50-I55, which are a part 
of the inserted peptide in L1 region of SQT-1C, were the amino acids with highest free energy contribution to the 
overall binding free energy. Conversely, the energy contribution of L2 residues, also located within the interaction 
interface, to the total binding energy is significantly smaller indicating that in NDS tetramers, L1 is more crucial 
for the oligomer formation. In comparison, for the DS dimer, residues L38-R65, comprising the β2, extended L1 
and β3 of the SQT-1C monomer and lie on the interface of the two domain-swapped chains have, unsurprisingly, 
ΔGTOT (kcal/mol)
NDS Cluster 1
tetramer −291 ± 25
dimer 1 −47 ± 6
dimer 2 −63 ± 9
NDS Cluster 2
tetramer* NC
dimer 1 −52 ± 10
dimer 2* NC
NDS Cluster 3
tetramer −177 ± 19
dimer 1 −29 ± 7
dimer 2 −34 ± 5
DS
tetramer −662 ± 24
dimer −337 ± 15
Table 2. MM-GB binding free energy of SQT-1C oligomers. *Denotes conformations that were not stable 
during MD simulations; no values were calculated for these conformations (NC).
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the biggest energy contributions to free energy of dimerisation. Meanwhile, residues located in L2 are crucial for 
formation of DS tetramers.
Overall, these results indicate that loop mediated SQT-1C tetramerisation via both NDS and DS mechanisms 
are energetically favourable, and hence possible in principle. However, the domain swapped mechanism results 
in much more stable oligomers, suggesting it is the preferred mechanism of SQT-1C oligomerisation in solution.
Discussion
The ability of protein scaffolds to retain their secondary and tertiary structure, and hence their structural, thermal 
and colloidal stability upon insertion of various peptide loops needed for their target-binding function is critical 
for their industrial or research applications. Small frame of such scaffolds needs to absorb additional steric strains 
introduced by the modified loops, and resist forming alternative conformations, such as domain-swapped con-
figuration. However, for small scaffold these may be more difficult to achieve than for large-size mAbs. Although 
the general conservation of secondary structure of the scaffold proteins can be easily assessed by Far-UV CD 
spectroscopy, important structural perturbations upon peptide insertions may not always be reflected at the sec-
ondary structure level, and therefore detailed assessment of tertiary and quaternary structure is required.
We show here that in the presence of 19% dioxane SQT-1C exists as a monomer in solution and also crystal-
lises as a monomer. However, in the absence of dioxane, SQT-1C monomer readily forms dimers and tetramers 
which co-exist in equilibrium. It is likely that the presence of high amounts of dioxane shifts the equilibrium 
towards the monomeric state46. The crystal structure reflects the dynamic nature of SQT-1C with higher than 
average B factors and less than ideal geometries (Table S1). However, despite these shortcomings, the backbone 
fold and lattice interactions can be confidently discerned and have been extensively validated. The slow times-
cale of SQT-1C oligomerisation when starting from isolated monomeric form indicates structural rearrange-
ment prior to oligomerisation, which is in line with a possible domain swap oligomerisation mechanism, typical 
for other proteins of the cystatin family35,47,48, despite SQT-1C being heavily modified in the loop regions in an 
attempt to engineer-out domain swapping28,29. However, we observed that SQT-1C oligomerisation is spontane-
ous under standard buffer conditions and reversible, whereas the DS dimerisation of non-mutated cystatins is 
known to occur only at elevated temperatures, low pH or in the presence of chemical denaturants, is irreversible 
and leads to loss of function36,49–51. Furthermore, SQT-1C does not form oligomers bigger than a tetramer, whilst 
Figure 5. MM-GBSA calculated per-residue contributions to total binding energy of SQT-1C complexes 
formed by NDS and DS mechanism. (a–d) Per residue total free energy contribution of amino acids to the 
stability of (a) NDS Cluster 1, (b) NDS Cluster 2, (c) NDS Cluster 3 and (d) DS SQT-1C tetramers, calculated 
with the MM-GBSA method. (e–h) Total energy contribution of each amino acid to the stability of tetramers 
projected to (e) NDS Cluster 1, (f) NDS Cluster 2, (g) NDS Cluster 3 and (h) DS SQT-1C tetramers. Both 
interaction interfaces are shown.
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domain-swapped and non-domain swapped oligomerisation in the cystatin family leads to fibril formation47,52. 
MM-GBSA calculations revealed that even though both NDS and DS SQT-1C tetramers are in principle ener-
getically favourable, the free energy of binding of DS oligomers was much lower, suggesting that such a complex 
would be more stable in solution compared to its NDS analogue.
Domain swapping in proteins, including in the cystatin family, is a well characterized process that is highly 
energetically favourable, but is traditionally believed to have a high activation energy due to large structural rear-
rangement, which can be overcome only in denaturing conditions36,53. It has been shown previously, however, 
that certain point mutations in cystatins can significantly increase the rate of domain swapping and amyloi-
dogenesis54–56. The effect of point mutations in the protein core on domain swap oligomerisation has been exten-
sively studied on various proteins, including B1 domain of the immunoglobulin G binding protein (GB1)57,58. 
Malevanets et al.59 simulated a monomer to domain swapped dimer transition of GB1 wildtype that does not form 
domain swapped oligomers in solution and its mutant that spontaneously oligomerises. They calculated a much 
flatter energy landscape than expected for this process and proposed that destabilization of the protein core due to 
mutagenesis might be crucial for DS to occur. A similar principle may be applied to SQT-1C, where either back-
bone mutations of SQT scaffold, insertion of peptides or a combination of both results in a destabilization of SQT 
structure that consequently lowers the energetic barrier for partial protein unfolding followed by domain swap, 
leading to a spontaneous formation of defined domain-swapped dimers which then form stable tetramers. It is 
reasonable to suggest that such a drastic conformational change driven by the inserted peptide relieves some of 
the strain introduced by an engineered loop. Consequently, conformation of the inserted peptide also drastically 
changes, from a hairpin to largely extended, which in turn influences its presentation for specific binding and rec-
ognition by the target protein. Further oligomerisation may cause an occlusion of the binding epitope. In case of 
SQT-1C tetramers, both inserted loops appear hidden within the interaction interface. Therefore, the question of 
which of the distinct states, monomer, dimer or tetramer, has the correct conformation for effective target binding 
will likely become important in determining the specific activity not only of SQT-1C, but also other engineered 
scaffolds which may suffer from the problems highlighted in the present case study.
In conclusion, we have used SQT-1C protein as a model system to study in detail the effect of peptide inser-
tions on secondary, tertiary and quaternary structures and have deduced that domain-swapping driven by 
inserted peptides is the most probable mechanism of forming well-defined dimers and tetramers. We also show 
that retained secondary structure does not necessarily mean that protein tertiary and quaternary structures 
are unperturbed. Therefore, protein aptamer designs should always be characterized at tertiary and quaternary 
structure levels, to reveal the conformation of the inserted target binding epitopes and identify which of the 
conformers, if several are present, are actually functionally competent. If insertion of peptide(s) leads to struc-
tural heterogeneity, approaches may be considered to stabilize the “active” conformation60,61. We also suggest 
that routine assessment using 2D 1H-15N correlation NMR spectra would reveal early problematic behaviour of 
designs, helping to troubleshoot protein instability and loss of structure, and confirm the presence or absence of 
well-behaved stable protein fold. Such NMR-driven assessment in combination with routine SEC-MALS charac-
terization would enable even faster development of protein aptamers with high specific binding activity attributed 
to a defined conformation, while minimizing unwanted behaviour such as aggregation and long-term instability.
Methods
plasmids. Synthesized codon-optimized gene construct encoding the SQT protein with AU1 insert in L1 and 
Myc insert in L228, named SQT-1, was obtained from GeneArt (ThermoFisher Lifetechnologies) and subcloned 
as two variants, with a cleavable hexa-histidine tag at the N-terminus (SQT-1N) or C-terminus (SQT-1C). Full 
sequences are presented in the Supplemental Materials and Methods.
Protein expression and purification. Both protein constructs were expressed in E. coli BL21 CodonPlus 
RP competent cells (Agilent Technologies) in lysogeny broth (LB) supplemented with 50 µg/mL ampicillin and 
34 μg/mL chloramphenicol (both Sigma Aldrich). LB was inoculated with 1% v/v overnight pre-culture. Cells 
were then grown at 37 °C with shaking until optical density at 600 nm (OD600) reached 0.8 at which point protein 
expression was induced with 0.5 mM IPTG. After overnight incubation at 37 °C cells were harvested by centrifu-
gation at 6000 g for 15 min. Uniformly 15N- and doubly 15N and 13C labelled samples were produced by growth in 
M9 minimal media supplemented with 15NH4Cl (99%), or both 15NH4Cl (99%) and 13C-D-glucose (99%) (both 
Sigma Aldrich), respectively.
Cell pellets were resuspended in denaturing buffer (20 mM NaPi, 500 mM NaCl, 6 M GndHCl, pH 8.0) 
with 0.5% v/v Triton X-100 (Sigma Aldrich) followed by lysis by sonication with Sonopuls HD 3200 ultrasonic 
homogenizer equipped with TT13/F2 probe (Bandelin). Lysate was then clarified by centrifugation at 30000 g 
for 30 min at 4 °C. Supernatant was transferred onto Ni-NTA resin (Quiagen) in a gravity flow column and incu-
bated for 90 min at 25 °C. Column was then washed with denaturing buffer supplemented with 10 mM imida-
zole. The bound material was eluted with 500 mM imidazole in denaturing buffer. Protein containing fractions 
were refolded by 1:10 rapid dilution in refolding buffer (20 mM NaPi, 150 mM NaCl, 5 mM EDTA, pH 7.2) fol-
lowed by one step overnight dialysis into refolding buffer. Finally, the protein was purified on HiLoad 26/600 
Superdex 200 pg column (GE Life Sciences) attached to ÄKTAPrime plus system (GE Healthcare Life Sciences), 
pre-equilibrated with refolding buffer. Both SQT variants eluted as a set of well-defined oligomers, which allowed 
isolation of monomeric, dimeric and tetrameric fractions, which were further concentrated using Vivaspin 20 
centrifugal device with a 5 kDa molecular weight cut-off (Sartorius Stedium Biotech GmbH). Protein concentra-
tions were estimated by measuring absorbance at 280 nm (ε = 14900 M−1 cm−1).
Molecular weights of SQT-1C oligomeric species were determined using size-exclusion chromatography cou-
pled with multi-angle light scattering (SEC-MALS) run at 25 °C; 500 μg of SQT-1C was separated on Superdex 
200 10/300GL column (GE Life Sciences) and passed through a Wyatt DAWN Heleos II EOS 18-angle laser 
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photometer (Wyatt Technology) coupled to a Wyatt Optilab rEX (Wyatt Technology) refractive index detector. 
Data analysis was performed in ASTRA 6.1 software (Wyatt Technology).
X-ray crystallography. Crystal screening of SQT-1C was conducted by sitting drop vapour diffusion, by 
mixing 200 nL of protein at 20 mg/mL in buffer (20 mM HEPES pH 7.2, 150 mM NaCl) with an equal volume of 
reservoir solution and incubating at 4 and 21 °C. Despite broad screening, crystals only formed at 4 °C when 38% 
v/v 1,4-Dioxane reservoir solution was added to freshly-prepared tetrameric fraction of SQT-1C, giving the final 
concentration of 19% dioxane in the droplet. Effect of 19% v/v dioxane on SQT-1C structure and oligomerization 
state in solution was further assessed using NMR and SEC-MALS. Crystals were cryo protected in perfluoropol-
yether cryo oil (PFO) prior to flash cooling in liquid nitrogen. Data were subsequently collected at io3 beamline 
at Diamond Light Source and scaled and merged with Xia262. Preliminary phases were obtained by molecular 
replacement in Phaser63 using a search model derived from Protein Data Bank (PDB) entry 3K9M. Iterative 
cycles of model building in Coot64 and refinement in Phenix.refine65 were used to generate the completed model. 
Validation with MolProbity66 was integrated into the iterative rebuild and refinement process. Complete data 
collection and refinement statistics are presented in Tables 1 and S1. The SQT-1C coordinates were deposited to 
PDB (ID 6QB2).
CD spectroscopy. Far-UV CD spectra were acquired on an Applied Photophysics Chirascan using a 0.01 cm 
path length quartz cell. The wavelength was varied from 190 to 280 nm with 0.5 nm step and acquisition time of 
3 s per point. CD measurements of individual oligomeric species were performed immediately after SEC step in 
protein purification at protein concentration of 1 mg/mL. Three scans were averaged and smoothed for each CD 
spectrum.
Intrinsic fluorescence. Melting temperature of SQT-1C was determined by measuring the change of intrin-
sic fluorescence maximum upon heating, using UNcle (Unchained labs). The temperature was varied from 20 to 
90 °C with heating rate 1 °C min−1. Melting temperature was determined using the first derivative method.
NMR experiments. NMR samples were prepared by adding 5% v/v 2H2O to 1 mM 15N- or 15N,13C- labelled 
protein solutions in refolding buffer. All NMR spectra were acquired at 25 °C on 800 MHz Bruker Avance III spec-
trometer equipped with 5 mm triple resonance TCI cryoprobe with temperature control unit. The spectra were 
acquired and processed using Bruker Topspin 3.5, and analysed using NMRFAM-SPARKY67, Dynamics Center 
2.2.4 (Bruker) and OriginPro 8.5.1 (OriginLabs).
NMR chemical shift assignment. For backbone assignment of SQT-1N, 2D 1H-15N HSQC and HSQC-based 
triple-resonance 3D HNCACB, HNCA, HNCO, HN(CA)CO and CBCA(CO)NH experiments from standard 
Bruker pulse program library were acquired using non-uniform sampling with multidimensional Poisson Gap 
scheduling strategy with sine bell weighting68. In addition, 3D TOCSY-HSQC and NOESY-HSQC with mixing 
times of 30 ms and 120 ms, respectively, were used to facilitate the assignment of SQT-1N. The backbone assign-
ment of SQT-1N was then transferred to SQT-1C by matching peak positions and verified using 3D TROSY-based 
HNCA and HNCO spectra, together with 3D TOCSY-HSQC and NOESY-HSQC with mixing times of 30 ms and 
120 ms, respectively.
Proton-deuterium exchange. After lyophilising the standard SQT-1C 0.5 mL NMR sample, it was quickly 
reconstituted in 0.5 mL of 2H2O and immediately placed into NMR spectrometer. A series of 10 BEST-TROSY 
experiments was acquired using pulse program b_trosyetf3gpsi.2 from standard Bruker library, with 6 min 20 s 
acquisition time per experiment. Decay of signal intensities was fitted to an exponential equation:
I t A Be( ) k tHD= + − ∗
where, A and B are arbitrary constants, I(t) is signal intensity at given time and kHD is rate of H/D exchange. 
Intrinsic exchange rates (kex) were calculated based on SQT-1C structure using SPHERE69, while protection fac-
tors (P) were calculated as kex/kHD ratio.
Molecular dynamics simulations. Molecular system. The SQT-1C X-ray structure was used as initial 
template into which the missing polypeptide stretches were added by multiple template homology modelling in 
I-TASSER38–40. SQT-1C oligomer models were obtained by ab-initio docking using the multi-body interface of 
HADDOCK 2.2 webserver41–43, see Supplementary Methods for full details. Three possible tetramer topologies 
were identified, and the lowest energy structure from each group was used in further MD simulations. SQT-1C 
dimers were obtained by separating tetramers into two subunits. SQT−1C domain swapped tetramer and dimer 
models were obtained by homology modelling using PDB ID 2OCT37 as a template.
Molecular dynamics simulations. MD simulations were performed in AMBER 1644 with ff99SB force field70. 
Protonation states of individual amino acids at pH 7.2 and ionic strength of 150 mM NaCl were assigned using 
H++ 3.2 webserver71,72 and kept constant throughout the MD simulations. Models were placed into an octahe-
dron box of TIP3P73,74 water molecules with the box border of at least 10 Å away from any atoms of the protein. 
Extra chloride or sodium ions were added to neutralize the charges of the protein complexes and achieve the 
final salt concentration of 150 mM NaCl. Prior to the production run of the MD simulations, the systems were 
subjected to a series of minimization, heating and pre-equilibration. The minimization protocol started with 
1000 steps of steepest descent minimization followed by 4000 steps of conjugate gradient minimization with 
10 kcal mol−1 Å−2 positional restraints on water molecules and backbone protein atoms. The system was then 
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heated from 10 to 300 K during 300 ps followed by 700 ps of initial equilibration at 300 K at constant temperature 
and volume. This was followed by a 1 ns pre-equilibration at a constant temperature of 300 K and a constant pres-
sure of 1 bar. The production simulations were carried out at constant temperature of 300 K, maintained using 
Langevin dynamics with collision frequency of 5.0 ps−1, and the same constant pressure. Periodic boundary con-
ditions were applied to all three Cartesian coordinates. Electrostatic interactions were calculated by the particle 
mesh Ewald method75,76 with the non-bonded cut-off set to 8 Å. The SHAKE algorithm77 was applied to bonds 
involving hydrogen atoms. The simulations were run for at least 120 ns with an integration step of 2 fs, and coor-
dinates were saved every 5 ps for further analysis of the simulations. For systems that did not converge within this 
timeframe, MD simulations were extended until convergence was reached for at least 20 ns. All trajectories were 
analysed using the CPPTRAJ module78 of AMBER 16. For each model, the energy-minimised structure (before 
the MD equilibration step) was chosen as a reference structure for RMSD and RMSF calculations.
The binding free energy calculation. The binding free energies of SQT-1C oligomers were calculated using the 
MM-GBSA method79 implemented in the AMBER program, using the coordinates extracted from the last 20 ns 
of the production MD runs at 40 ps intervals. In the GB calculation, variables α, β and γ were set to 0.8, 0.0 and 
2.90922580,81. Binding free energy contributions of all residues were extracted using the energy decomposition 
scheme as implemented in AMBER82. Based on the individual contributions to the binding free energy, amino 
acid residues with significantly higher than average energy contribution (>2.5 kcal/mol) were considered as inter-
action hotspots. Solvent accessible surface areas (SASA) of all SQT-1C oligomer models were calculated using 
GETAREA webserver83 and compared to SASA of monomeric SQT-1C.
Accession Codes. The atomic coordinates for the SQT-1C crystal structure have been deposited to the 
Research collaborator for Structural bioinformatics Protein Databank under PBD ID 6QB2. NMR backbone 
assignment of SQT-1N has been submitted to BioMagResBank under accession code 27757.
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